{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:30:41Z","timestamp":1786980641959,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1007\/s10350-007-9008-3","type":"journal-article","created":{"date-parts":[[2007,8,17]],"date-time":"2007-08-17T03:58:04Z","timestamp":1187323084000},"page":"1747-1753","source":"Crossref","is-referenced-by-count":107,"title":["Does Infliximab Influence Surgical Morbidity of Ileal Pouch-Anal Anastomosis in Patients with Ulcerative Colitis?"],"prefix":"10.1097","volume":"50","author":[{"given":"Stefanie J.","family":"Schluender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ippoliti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla","family":"Dubinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Vasiliauskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos A.","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan R.","family":"Targan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip R.","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"9008_CR1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/gut.50.2.206","volume":"50","author":"T Hove ten","year":"2002","unstructured":"ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn\u2019s disease. Gut 2002;50:206-1.","journal-title":"Gut"},{"key":"9008_CR2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group. N Engl J Med 1997;337:1029-5.","journal-title":"N Engl J Med"},{"key":"9008_CR3","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-6.","journal-title":"N Engl J Med"},{"key":"9008_CR4","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1053\/j.gastro.2006.01.048","volume":"130","author":"GR Lichtenstein","year":"2006","unstructured":"Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940-7.","journal-title":"Gastroenterology"},{"key":"9008_CR5","first-page":"A617","volume":"122","author":"A Brzezinski","year":"2002","unstructured":"Brzezinski A, Armstrong L, Alvarez del Real G, Parsi M, Lashner B, Achar JP. Infliximab does not increase the risk of complications in the perioperative period in patients with Crohn\u2019s disease [abstract]. Gastroenterology 2002;122:A617.","journal-title":"Gastroenterology"},{"key":"9008_CR6","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1572-0241.2004.04148.x","volume":"99","author":"JF Colombel","year":"2004","unstructured":"Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn\u2019s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004;99:878-3.","journal-title":"Am J Gastroenterol"},{"key":"9008_CR7","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1365-2036.2004.01904.x","volume":"19","author":"L Marchal","year":"2004","unstructured":"Marchal L, D\u2019Haens G, Van Assche G, et al. The risk of postoperative complications associated with infliximab therapy for Crohn\u2019s disease: a controlled cohort study. Aliment Pharmacol Ther 2004;19:749-4.","journal-title":"Aliment Pharmacol Ther"},{"key":"9008_CR8","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1007\/BF02234594","volume":"44","author":"GM Hyde","year":"2001","unstructured":"Hyde GM, Jewell DP, Kettlewell MG, Mortensen NJ. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001;44:1436-0.","journal-title":"Dis Colon Rectum"},{"key":"9008_CR9","first-page":"671","volume":"48","author":"S Ognibene","year":"2005","unstructured":"Ognibene S, Vasiliauskas EA, Dubinsky MC, et al. Long-term effects of cyclosporine A on morbidity after colectomy for ulcerative colitis: a word of caution [meeting abstract]. Dis Colon Rectum 2005;48:671.","journal-title":"Dis Colon Rectum"},{"key":"9008_CR10","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.4049\/jimmunol.139.10.3406","volume":"139","author":"TE Ulich","year":"1987","unstructured":"Ulich TE, del Castillo J, Keys M, Granger GA, Ni RX. Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha-induced changes in circulating numbers of neutrophils and lymphocytes. J Immunol 1987;139:3406-5.","journal-title":"J Immunol"},{"key":"9008_CR11","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1126\/science.3933111","volume":"230","author":"B Sugarman","year":"1985","unstructured":"Sugarman B, Aggarwal B, Hass P, Figari I, Palladino M, Shepard H. Recombinant human tumor necrosis factor-alpha effects on proliferation of normal and transformed cells in vitro. Science 1985;230:943-.","journal-title":"Science"},{"key":"9008_CR12","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1084\/jem.172.6.1749","volume":"172","author":"AE Postlethwaite","year":"1990","unstructured":"Postlethwaite AE, Seyer JM. Stimulation of fibroblast chemotaxis by human recombinant tumor necrosis factor (TNF-\u03b1) and a synthetic TNF-\u03b1 31-8 peptide. J Exp Med 1990;172:1749-6.","journal-title":"J Exp Med"},{"key":"9008_CR13","doi-asserted-by":"crossref","first-page":"C1971","DOI":"10.1152\/ajpcell.2001.281.6.C1971","volume":"281","author":"J Albina","year":"2001","unstructured":"Albina J, Mastrofrancesco B, Vessella J, et al. HIF-1 expression in healing wounds: HIF-1alpha induction in primary inflammatory cells by TNF-alpha. Am J Physiol Cell Physiol 2001;281:C1971-.","journal-title":"Am J Physiol Cell Physiol"},{"key":"9008_CR14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1524-475x.2000.00547.x","volume":"8","author":"L Lee","year":"2000","unstructured":"Lee L, Efron D, Tantry U, et al. Inhibition of tumor necrosis factor-alpha attenuates wound breaking strength in rats. Wound Rep Reg 2000:8:547-3.","journal-title":"Wound Rep Reg"},{"key":"9008_CR15","doi-asserted-by":"crossref","first-page":"8093","DOI":"10.1073\/pnas.94.15.8093","volume":"94","author":"MW Marino","year":"1997","unstructured":"Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 1997;94:8093-.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9008_CR16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0016-5085(99)70224-6","volume":"116","author":"FJ Baert","year":"1999","unstructured":"Baert FJ, D\u2019Haens GR, Peeters M, et al. Tumor necrosis factor-alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn\u2019s ileocolitis. Gastroenterology 1999;116:22-.","journal-title":"Gastroenterology"},{"key":"9008_CR17","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"A Warris","year":"2001","unstructured":"Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001;345:1098-04.","journal-title":"N Engl J Med"},{"key":"9008_CR18","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/gut.2003.018515","volume":"53","author":"T Ljung","year":"2004","unstructured":"Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population-based cohort from Stockholm County. Gut 2004;53:849-3.","journal-title":"Gut"},{"key":"9008_CR19","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise R, et al. Tuberculosis associated with infliximab, a tumor necrosis factor- \u03b1 neutralizing agent. N Engl J Med 2001;345:1098-04.","journal-title":"N Engl J Med"},{"key":"9008_CR20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","volume":"126","author":"JF Colombel","year":"2004","unstructured":"Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn\u2019s disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004;126:19\u201331.","journal-title":"Gastroenterology"},{"key":"9008_CR21","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/BF02049146","volume":"38","author":"PR Fleshner","year":"1995","unstructured":"Fleshner PR, Michelassi F, Rubin M, Hanauer SB, Plevy SE, Targan SR. Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin. Dis Colon Rectum 1995;38:1241-.","journal-title":"Dis Colon Rectum"}],"container-title":["Diseases of the Colon & Rectum"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00003453-200750110-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T16:37:55Z","timestamp":1683995875000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003453-200750110-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1007\/s10350-007-9008-3","relation":{},"ISSN":["0012-3706"],"issn-type":[{"value":"0012-3706","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}